Clinical Trial

Opioid Drug Interaction Study

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will examine the effects of doses of opioid/placebo and doses of alprazolam/placebo, alone and in combination. The primary outcomes are pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) and pharmacokinetic outcomes (from blood samples) to determine the interaction effects of these compounds.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-01-01; most recent amendment 2026-05-13.
Status change: Not Yet Recruiting → Recruiting 2025-03-21
Trial Details
NCT Number NCT06757140
Lead Sponsor Shanna Babalonis, PhD
Collaborators: National Institute on Drug Abuse (NIDA)
Conditions Drug Interactions, Drug Kinetics
Enrollment 25 participants
Start Date 2025-04-01
Primary Completion 2029-01-01 (estimated)
Study Completion 2029-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-14